

Nom : JANSSENS
Prénom : Jean-Paul

Publications concernant la tuberculose et les mycobactéries environnementales

1. Vongthilath-Moeung R, Plojoux J, Poncet A, Renzi G, Veziris N, Schrenzel J, Janssens JP. Nontuberculous mycobacteria under scrutiny in the Geneva area (2015-2020) Submitted to **Respiration**. (Feb 2021). IF : 3.32
2. Pham TT, Schrenzel J, Janssens JP, Emonet S. Performances and usefulness of Xpert MTB/RIF assay in low-incidence settings: not that bad? **Eur J Clin Microbiol Infect Dis**. 2020 Sep;39(9):1645-1649. IF: 2.83
3. d'Incau S, Vargas MI, Calmy A, Janssens JP. *Mycobacterium fortuitum* disseminated infection in an immunocompetent patient without predisposing factors. **BMJ Case Rep**. 2020 Sep 29;13(9):e235842. IF : 0.44
4. Guglielmi S, Guglielmi G, Mönig S, Janssens JP, Spahr L. Miliary tuberculosis with mediastinal and cervical lymph node involvement complicated by an eso-mediastinal fistula. **Int Gast Hepatol** 2019; 2: 176-179. IF: 2.97
5. Berra G, Plojoux J, Soccia PM, Janssens JP. Identification of Non-Tuberculous Mycobacteria in COPD Patients Undergoing Lung Volume Reduction: More Frequent than Expected? **Respiration**. 2019;98(3):279-280. IF: 3.32
6. Grira M, Boulvain M, Janssens JP. Inflammatory Syndrome as the Initial Manifestation of Retroperitoneal Tuberculosis in a Pregnant Woman. **Eur J Case Rep Intern Med**. 2018 Jul 26;5(7):000865. eCollection 2018. IF: n.a.
7. De Stefano P, Lascano AM, Schibler M, Fitsiori A, Janssens JP, Lalive PH, Gschwind M. Pachymeningitis with optic neuropathy associated with extrapulmonary tuberculosis and secondary antiphospholipid syndrome. **Mult Scler Relat Disord**. 2019 Apr;29:83-85. IF: 2.88
8. Auer C, Kiefer S, Zuske M, Schindler C, Wyss K, Blum J, Bosch-Capblanch X, Widmer U, Sauthier S, Janssens JP, Bossard K, Chatonnet C, Mazza-Stalder J, Začek B, Zellweger JP, Altpeter E, Mäusezahl M. Health-seeking behaviour and treatment delay in patients with pulmonary tuberculosis in Switzerland: some slip through the net. **Swiss Med Wkly**. 2018 Sep 6;148:w14659. IF: 1.82
9. Bothamley GH, Lange C; TBNET. Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trials group (TBNET) study. **Respir Med**. 2017 Nov;132:68-75. IF: 3.47
10. Janssens JP, Wullemin T, Adler D, Jackson Y. Screening for tuberculosis in an urban shelter for homeless in Switzerland: a prospective study. **BMC Infect Dis**. 2017 May 16;17(1):347. IF: 1.57
11. Lolachi S, Janssens JP, Adler D. Tuberculous meningitis: what's new? **J Neuroinfect Dis**, 2017, 8: 248
12. Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L. Standard Genotyping Overestimates

- Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. **J Clin Microbiol.** 2016; 54: 1862-70. Impact factor : 3.63
13. Lange C, van Leth F, Sester M; TBnet.. Viral Load and Risk of Tuberculosis in HIV Infection. **J Acquir Immune Defic Syndr.** 2016; 71(2): e51-3. Impact factor : 3.8
 14. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Fløe A, Fresard I, García-García JM, Goletti D, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Ruiz AS, Solovic I, Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET. Risk Assessment of Tuberculosis in Contacts by IFN- γ Release Assays. A Tuberculosis Network European Trials Group Study. **Am J Respir Crit Care Med.** 2015; 191: 1176-84. Impact factor : 13.11
 15. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccacal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET.. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. **Am J Respir Crit Care Med.** 2014; 190: 1168-76. Impact factor : 12.99
 16. Bourigault ML, Vacher R, Rose S, Olleros ML, Janssens JP, Quesniaux VF, Garcia I. Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. **Am J Clin Exp Immunol.** 2013; 2: 124-34. Impact factor: n.a.
 17. K Hadaya, PO Bridevaux, P Roux-Lombard, A Delort, P Saudan, PY Martin, JP Janssens. Contribution of interferon gamma release assays (IGRAs) to the diagnosis of latent tuberculosis infection after renal transplantation. **Transplantation** 2013; 95: 1485-90. Impact factor: 3.53
 18. Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder HL, Zwahlen M, Hoffmann M, Bernasconi E, Cavassini M, Calmy A, Dolina M, Frei R, Janssens JP, Borrell S, Stucki D, Schrenzel J, Böttger EC, Gagneux S; Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. **PLoS Genet.** 2013 Mar; 9(3): e1003318. Impact factor: 8.69
 19. Fenner L, Gagneux S, Janssens JP, Fehr J, Cavassini M, Hoffmann M, Bernasconi E, Schrenzel J, Bodmer T, Böttger EC, Helbling P, Egger M; Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. **PLoS One.** 2012; 7: e3418. Impact factor: 4.09
 20. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Böttger EC, Egger M; Swiss HIV Cohort Study Group; Molecular Epidemiology of Tuberculosis Study Group. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. **J Clin Microbiol.** 2012; 50: 388-95. Impact factor: 4.15
 21. Mazza-Stalder J, Nicod L, Janssens JP. [Extrapulmonary tuberculosis]. **Rev Mal Respir.** 2012; 29: 566-78. Impact factor: 0.59
 22. Ninet B, Roux-Lombard P, Schrenzel J, Janssens JP. [New tests for the diagnosis of tuberculosis]. **Rev Mal Respir.** 2011; 28: 823-33. Impact factor: 0.59
 23. Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. **Swiss Med Wkly.** 2011; 141: w13240. Impact factor: 1.89
 24. Blanc FX, Janssens JP, Underner M. [Tuberculosis and non-tuberculous mycobacteria: Respiratory medicine on pole position]. **Rev Mal Respir.** 2011;28: 404-6. Impact factor: 0.59

25. Wolff H, Janssens JP, Bodenmann P, Meynard A, Delhumeau C, Rochat T, Sudre P, Costanza MC, Gaspoz JM, Morabia A. Undocumented migrants in Switzerland: geographical origin versus legal status as risk factor for tuberculosis. **J Immigr Minor Health** 2010; 12: 18-23.
26. Kherad O, Herrmann FR, Zellweger JP, Rochat T, Janssens JP. "Outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva Switzerland". **BMC Infectious Diseases**, 2009; 9: 217. Impact factor: 2.53 (*)
27. Bosshard V, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T, Janssens JP. "Do results of the T-SPOT.TB interferon gamma release assay change after treatment of tuberculosis?" **Respir Med** 2009; 103: 30-4. Impact Factor: 2.08
28. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, Panizzon RG, Saurat JH. "Tuberculosis screening in psoriasis patients before anti-TNF therapy: Comparison of an interferon-gamma release assay versus tuberculin skin test". **British Journal Dermatology** 2009; 161: 797-800. Impact factor: 3.49
29. Tardin A, Dominice Dao M, Ninet B, Janssens JP. "Tuberculosis cluster in an immigrant community: case identification issues and a transcultural perspective". **Trop Med Intern Health** 2009; 14: 995-1002. Impact factor: 2.13
30. ML Olleros, D Vesin, AF Lambou, JP Janssens; B Ryffel, S Rose, C Fremond, VF Quesniaux, DE Szymovski, I Garcia "Dominant-Negative TNF Protects from Mycobacterium bovis BCG and Endotoxin-Induced Liver Injury Without Compromising Host Immunity to BCG and M. tuberculosis". **J Infect Dis** 2009; 199: 1053-63. Impact Factor: 6.0
31. Triverio PA, Bridevaux PO, Roux-Lombard P, Niksic L, Rochat T, Martin PY, Saudan P, Janssens JP. "Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in haemodialysis patients". **Nephrol Dial Transplant** 2009; 24: 1952-6. Impact factor : 3.56
32. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. **Eur Respir J**. 2009; 34: 387-93. Impact Factor: 5.07
33. Toutous-Trellu L, Charlet I, Hirschel B, Prins C, Masouyé I, Vischer UM, Janssens JP. Tuberculous Cutaneous Ulcers Associated with Miliary Tuberculosis in an Elderly Woman. **Case Rep Dermatol**. 2009 Aug 28;1:23-28.
34. JP Janssens, P Roux-Lombard, T Perneger, M Metzger, RVivien, T Rochat. "Contribution of a IFN-gamma assay in contact tracing for tuberculosis in a low-incidence, high immigration area". **Swiss Med Wkly** 2008; 138: 585-93. Impact Factor: 1.35
35. JP Janssens, HL Rieder. "An ecologic analysis of incidence of tuberculosis and per capita gross domestic product". **Eur Respir J** 2008; 32: 1415-6. Impact Factor: 5.07
36. Bothamley GH, Ditui L, Migliori GB, Lange C; TBNET Contributors. "Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey". **Eur Respir J** 2008; 32: 1023-30. Impact Factor: 5.07
37. E Lankensjold, F Herrmann, BL Luong, T Rochat, JP Janssens. "Contact tracing for tuberculosis and treatment for latent infection in a low incidence country". **Swiss Med Wkly** 2008; 138: 78-84. Impact factor: 1.35
38. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP. "Indeterminate test results of T-SPOT.TB performed under routine field conditions." **Eur Respir J** 2008; 31: 842-6. Impact Factor: 5.07

39. JP Janssens. "Clinical utility of the interferon-gamma release assay for elderly patients with active tuberculosis: a word of caution". **Chest** 2008, 134: 471-2. Impact Factor: 4.01
40. A Silivan, JP Janssens. Comment on "Active screening for pulmonary tuberculosis by chest X-ray among immigrants at the Swiss border". C Mathez; Y Bangala; P Bady, JP Zellweger. **Swiss Med Wkly** 2008; 138: 355-6. Impact factor: 1.35
41. JP Janssens. "Interferon- γ release assay to rule out active tuberculosis". **Eur Respir J** 2007; 30: 183-4. Impact Factor: 5.07
42. JP Janssens, P Roux-Lombard, T Perneger, M Metzger, RVivien, T Rochat. "Quantitative scoring of a γ -interferon assay for differentiating active from latent tuberculosis." **Eur Respir J** 2007: 30: 722-8. Impact Factor: 5.07 (*)
43. AB Younossian, L Favre, T Rochat, JP Janssens. "Ascites and elevated serum CA-125 level in a case of peritoneal tuberculosis". **Scand J Infect Dis** 2006; 38: 216; Impact Factor: 1.12
44. J Habas-Rubio, JP Janssens, T Rochat, E Sforza. "REM-related disordered breathing: clinical and polysomnographic features". **Chest** 2005; 128: 3350-7; Impact Factor: 4.01.
45. AB Younossian, T Rochat, JP Ketterer, J Wacker, JP Janssens. "High hepatotoxicity of Pyrazinamide and Ethambutol for treatment of latent tuberculosis". **Eur Respir J** 2005; 26: 1-3; Impact Factor: 3.95
46. A Laszlo, S Gianelli, F Laurencet, KH Krause, JP Janssens. "Successful treatment of disseminated tuberculosis and acquired immunodeficiency syndrome in an 81-year old woman". **Scand J Infect Dis** 2003; 35 :420-2; Impact Factor: 1.12
47. JP Janssens, JP Zellweger . "Spécificités de l'épidémiologie, de la clinique et du traitement de la tuberculose chez les personnes âgées". (Peer-reviewed article). **Schweiz med Wschr** 1999; 129: 80-89
48. JP Janssens, R de Haller : "Spinal tuberculosis in a developed country: a review of 26 cases with special emphasis on abscesses and neurological complications". **Clinical Orthopaedics and Related Research**; 1990; 257: 67-75

Articles publiés dans des journaux sans politique éditoriale:

1. Vongthilath R, Gasche-Soccal P, Roux-Lombard P, Janssens JP. Dépistage de l'infection tuberculeuse latente chez les patients immunosupprimés non infectés par le VIH [Screening for latent tuberculosis infection in immunosuppressed patients not infected with HIV]. **Rev Med Suisse**. 2019 Nov 13;15(671):2105-2108.
2. Del Puppo L, Janssens JP, Kherad O, Younossian AB, Frésard I. [Bone tuberculosis: when to consider this diagnosis?]. **Rev Med Suisse**. 2016; 12: 262-5.
3. Janssens JP. Rôle des IGRAs dans le diagnostic et le suivi de la tuberculose du sujet âgé. La gazette médicale. **Info Geriatrie**. Mars 2015. P 31
4. Hungerbühler P, Janssens JP. [Is tuberculosis easier to diagnose?]. **Rev Med Suisse**. 2014; 10: 404-5.
5. Lyashchenko KP, Greenwald R, Esfandiari J, Lecu A, Waters WR, Posthaus H, Bodmer T, Janssens JP, Aloisio F, Graubner C, Grosclaude E, Piersigilli A, Schiller I. Pulmonary Disease due to Mycobacterium tuberculosis in a Horse: Zoonotic Concerns and Limitations of Antemortem Testing. **Vet Med Int**; 2012: 642 : 145.
6. Charbonnier F, Calmy A, Janssens JP. [Tuberculosis and HIV co-infection: a therapeutic challenge]. **Rev Med Suisse**. 2011; 7: 2295-6, 2298-300.

7. Lechartier B, Mazza-Stalder J, Janssens JP, Nicod LP. [Latent M. tuberculosis infection, update 2011]. **Rev Med Suisse**. 2011; 7: 2289-94.
8. JP Janssens. "Nouveaux tests diagnostiques de la tuberculose : sont-ils contributifs chez le sujet âgé ? ". **Gériatrie Pratique 2008**.
9. JP Janssens. "Approche critique de l'utilisation des tests mesurant le γ -interferon lors de suspicion de tuberculose : cas cliniques". **Rev Med Suisse** 2006; 2: 2620-5.

Doctorats en médecine

1. "Aspects spécifiques de la tuberculose du sujet âgé: données anatomo-pathologiques". Dr M. Fuertes, Thèse N° 10362, 2004
2. "Tuberculosis in asylum seekers in the canton of Geneva: a 5-year retrospective study". Dr A Silivan ; Thèse N°10530, 2008
3. "Results of contact tracing procedures for tuberculosis, and treatment for latent tuberculous infection in a low incidence country over a 10-year period (1993-2002)" Dr E Lankensjold, Thèse N°10570, 2009 (published in Swiss Med Wkly. 2008 Feb 9;138(5-6):78-84)
4. "Tuberculosis in Geneva: a 4-year retrospective study of 250 cases". Dr O Kherad; 2010
5. "Do results of the T-SPOT.TB interferon gamma release assay change after treatment of tuberculosis?". V Bosshard; 2010.
6. "Inflammatory Syndrome as the Initial Manifestation of Retroperitoneal Tuberculosis in a Pregnant Woman". Grira M. 2020

Travaux de Master (médecine) :

Infection pulmonaire à *Mycobacterium Xenopi* : revue de cas pour lesquels la contamination environnementale a été établie, et revue de la littérature. F. Sierro, 2014.



Genève, le 07.03.2021

Citation report for 210 results from Web of Science Core Collection between and

You searched for: Article Group for: Janssens, Jean-Paul ...[More](#)

This report reflects citations to source items indexed within Web of Science Core Collection. Perform a Cited Reference Search to include citations to items not indexed within Web of Science Core Collection.

Export Data: ▾

<p>Total Publications </p> <p>210 Analyze</p> <p>2001 2020</p>	<p>h-index </p> <p>38</p> <p>Average citations per item</p> <p>24,63</p>	<p>Sum of Times Cited </p> <p>5 172</p> <p>Without self citations</p> <p>4 893</p>	<p>Citing articles </p> <p>4 414 Analyze</p> <p>Without self citations</p> <p>4 320 Analyze</p>
--	---	---	--

